Pharmacometabolomic Pathway Response of Effective Anticancer Agents on Different Diets in Rats with Induced Mammary Tumors

Metabolomics is an effective approach to characterize the metabotype which can reflect the influence of genetics, physiological status, and environmental factors such as drug intakes, diet. Diet may change the chemopreventive efficacy of given agents due to the altered physiological status of the subject. Here, metabolomics response to a chemopreventive agent targretin or tamoxifen, in rats with methylnitrosourea-induced tumors on a standard diet (4% fat, CD) or a high fat diet (21% fat, HFD) was evaluated, and found that (1) the metabolome was substantially affected by diet and/or drug treatment; (2) multiple metabolites were identified as potential pharmacodynamic biomarkers related to targretin or tamoxifen regardless of diet and time; and (3) the primary bile acid pathway was significantly affected by targretin treatment in rats on both diets, and the lysolipid pathway was significantly affected by tamoxifen treatment in rats on the high fat diet.

[1]  V. Steele,et al.  5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target? , 2016, Cancer Prevention Research.

[2]  V. Steele,et al.  Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes , 2008, Molecular Cancer Therapeutics.

[3]  V. Steele,et al.  Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis , 2009, Cancer Prevention Research.

[4]  V. Steele,et al.  Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. , 1994, Anticancer research.

[5]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[6]  W. J. Visek,et al.  The combined effects of dietary protein and fat on 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats. , 1984, The Journal of nutrition.

[7]  V. Steele,et al.  Lack of Effect of Metformin on Mammary Carcinogenesis in Nondiabetic Rat and Mouse Models , 2015, Cancer Prevention Research.

[8]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[9]  Lining Guo,et al.  Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats , 2009, Toxicologic pathology.

[10]  R. Lubet,et al.  Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents , 2018, Cancer Prevention Research.

[11]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[12]  V. Steele,et al.  Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. , 2004, Carcinogenesis.

[13]  V. Steele,et al.  Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. , 1998, Carcinogenesis.

[14]  M. You,et al.  Global molecular changes in rat livers treated with RXR agonists: a comparison using transcriptomics and proteomics , 2014 .

[15]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[16]  Kosuke Saito,et al.  Arachidonic acid‐containing phosphatidylcholine characterized by consolidated plasma and liver lipidomics as an early onset marker for tamoxifen‐induced hepatic phospholipidosis , 2017, Journal of applied toxicology : JAT.